TW Webinars

There is a high unmet needs in HCC patients have Child-Pugh B liver function status. The safety profile of nivolumab in patients with Child-Pugh B status appears comparable to that observed in patients with Child-Pugh A status. Nivolumab monotherapy demonstrated durable responses in patients with Child-Pugh B advanced HCC. Nivolumab showed promising efficacy and tolerability in patients with Child-Pugh B status, supporting further investigation in this patient population.

In this video, Dr. Yu-Chieh Tsai is going to talk about the newly evidence of immunotherapy-based therapeutic strategy in treatment with GU cancer. The PC session will deliver and analysis the data of CheckMate 650, IO-IO combination in treatment with mCRPC. The RCC session will update the long-term OS in CheckMate 214, IO-IO combination in treatment with mRCC. Finally, The UC session will introduce a potential combination therapy strategy of Nivolumab combine NKTR-214 in 1L UC.

Esophageal cancer is the seventh most common cancer but sixth leading cause of death after lung, colorectal, stomach, liver and breast cancers. Approximately 508 585 deaths were reported worldwide in 2018. The incidence has declined from about 2.8 to 1.2 per 100 000 people for esophageal squamous-cell carcinoma, whereas the incidence has increased from 0.4 to 2.8 per 100 000 in the USA and Europe, from the mid-1970s to 2012. Esophageal cancer is an Asian predominant disease with high prevalence of squamous-cell histology. In 2002, 92·9% of all Japanese esophageal carcinomas were squamous-cell carcinomas, and lesions were mostly found in the middle thoracic esophagus. In Taiwan, number of patients with newly diagnosed esophageal cancer in was 2610 in 2016 with 92% of them being squamous cell carcinoma. Conventional chemotherapies, including 5-Fu, cisplatin and taxanes, are used at first- and second-line setting but unfortunately, with lack of durable benefit. Patients with disease progression have limited treatment options. With the rapid expansion of anti-PD1/ anti-PD-L1 immunotherapy in different indications, recently phase 3 trials on second-line treatment for esophageal cancer has been released. This talk will focus on the new data outcomes and their implications. Strategies to treat esophageal carcinomas are desperately needed for this population.

In these video, Dr. Tsai and Dr. Hsia are going to talk about the newly evidence of immunotherapy-based combination strategy in treatment with advanced NSCLC. The session will deliver and analysis the evidence of CheckMate227 published @ESMO 2019 congress.

In these video, Dr. Tsai and Dr. Hsia are going to talk about the newly evidence of immunotherapy-based combination strategy in treatment with advanced NSCLC. The session will deliver and analysis the evidence of CheckMate227 published @ESMO 2019 congress.